Indexed in ProQuest Data base Abstracts, USA: (ProQuest Science Journals; ProQuest Health and Medical Complete). EBSCO Data base, USA.
Pharmacology & Therapy » Past Abstracts
Electronic Journal of Pharmacology & Therapy, 7: 1-4 (2014)
1. Ormeloxifene; medical management of dysfunctional uterine bleeding
Kaur, S., Kaur, S., Mittal, R., Mittal N. and  Shruti,
Department of Obst & Gynae, M. M. Medical College Kumarhatti, Solan ( HP ).
 E mail:, Cell: 073075 85558

Abstract: To evaluate  the  efficacy of  Ormeloxifene  in  DUB. Medical  management  of  DUB  is  a  challenging  task  and  many  drugs  are  available for  this  condition  but  show  lack  of  consensus for medical  treatment.   Ormeloxifene  mediates  its effects  by  high  affinity  interaction  with  ER,  antagonizing  the  effect  of  estrogen  on  uterine and  breast  tissue  and  agonizing  the  effect  on  vagina,  bone,  cardiovascular system.  So it  is  suitable for  medical  management  of  DUB. Sixty five women  aged  between 30 to 50  were  recruited  for  the  study  whom  chief  complaint was  heavy  menstrual  flow.  Ormeloxifene 60 mg was given  orally  twice  in  a week  for  first  12  weeks followed  by  once  in  a  week  for  next  12  weeks.  Menstrual  blood loss  measurements  using  subjective  assessment  of  amount  of  flow,  blood hemoglobin  and  endometrial  thickness were the  main  measurements  to  evaluate  the  efficacy of  therapy.  Statistical  analysis  was  done  using a  paired ‘t‘  test  and  ‘z‘  test. The  difference  in  mean  heamoglobin  concentration of  1.31gm/dl between  pretreatment  and  post-treatment  levels  was  also  statisticallysignificant (P<0.001).  87.05% showed a  reduction  in  endometrial  thickness  as  assessed  by  transvaginalsonography.  8.2%  women  needed  hysterectomy.  Ormeloxifene is an effective drug therapy  in  medical  management  of DUB.

 Key words: Ormeloxifene , Menorrhagia

Electronic Journal of Pharmacology & Therapy, 7: 5-7 (2009)
2. Extensive utilization of cell culture based  vaccines in the modern scenario
Jainth, S. and Gupta, M.
Department of Scientific Research, Mahatma Jyoti Rao Phoole University, Jaipur (Rajasthan).
E. mail:
Abstract: Hopes of growing poliovirus in the lab without the use of live animals drove many of the researchers in the 1930s and 1940s. Cell cultures involve growing cells in a culture dish, often with a supportive growth medium like collagen. They offer a level of control that was unavailable using live animals, and can also support large-scale virus production. (For more about cell cultures and cell lines, as well as cell lines made using human cells, see our article “Human Cell Strains in Vaccine Development.”) Early efforts to grow poliovirus in culture, however, repeatedly ended in failure. In 1936, Albert Sabin and Peter Olitsky at the Rockefeller Institute successfully grew poliovirus in a culture of brain tissue from a human embryo. The virus grew quickly, which was promising, but Sabin and Olitsky were concerned about using this as starting material for a vaccine, fearing nervous system damage for vaccine recipients. They tried to grow poliovirus in cultures using tissue that had been taken from other sources, but were unsuccessful. Today, many different animal cell strains are available for use in scientific research and development. Several vaccines currently available in the United States were developed using the Vero cell line, started from African green monkey kidney cells: Rotavirus vaccines (Rotarix/GlaxoSmithKline, RotaTeq/Merck), Polio (IPOL/Sanofi Pasteur). Smallpox (ACAM2000/Sanofi Pasteur – Used only for selected military personnel). Japanese encephalitis (Ixiaro/Intercell – Used only for those traveling to areas with known outbreaks of disease). Future U.S. vaccines may use other animal cell strains, including the Madin Darby Canine Kidney (MDCK) line, which was started in 1958 with kidney cells from a cocker spaniel. (Some European vaccines are already made using MDCK.)
Key words: Cell cultures based vaccines

Copyright © 2019 - CTR Publications, All Right Reserved.
Web Solutions :: Impex Solutions